Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate Lucid-MS for multiple sclerosis and pursuing commercial growth with its unbuzzd product, according to Executive Co-Chairman and Co-Founder Anthony Durkacz in a recent BioMedWire Podcast interview. The company’s dual strategy combines clinical-stage pharmaceutical development with commercial opportunities targeting neurodegenerative, metabolic and alcohol-misuse conditions.
Durkacz highlighted Lucid-MS’s goal of addressing mobility damage associated with MS. The company has filed an investigational new drug application for a Phase 2 clinical trial, which could mark the first administration of the candidate to human MS patients. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, which is the underlying mechanism of multiple sclerosis.
On the commercial front, Durkacz discussed unbuzzd, a product designed to accelerate alcohol metabolism. Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains ownership of 19.84% of UWI (as of March 31, 2026) and receives royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar pharmaceutical and medical formulations.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company focuses on research and development of Lucid-MS. The company’s approach combines clinical-stage drug development with commercial products like unbuzzd, which is already available on the market.
The podcast appearance underscores Quantum BioPharma’s efforts to communicate its strategy to investors and the public. The full interview is available at https://ibn.fm/IWnPQ. More information about the company can be found in its newsroom at https://ibn.fm/QNTM.
